Grown Rogue International (GRUSF) Profit After Tax (2009 - 2026)
Grown Rogue International's (GRUSF) quarterly Profit After Tax came in at -$2.7 million in Q1 2026, down 463.75% year-on-year from $742870.0 in Q1 2025, and up 100.0% quarter-over-quarter from -$5335.5 billion in Q4 2025.
Grown Rogue International (GRUSF) Profit After Tax (2009 - 2026) Analysis & Trends
Grown Rogue International's Profit After Tax history runs 18 years deep, the most recent figure standing at -$2.7 million for Q1 2026.
- On a quarterly basis, Profit After Tax fell 463.75% year-over-year to -$2.7 million in Q1 2026; TTM through Mar 2026 was -$2500.4 billion, a 121.3% decrease from a year earlier, with the FY2025 full-year figure at -$622811.0, up 96.1% from the prior year.
- Profit After Tax climbed to -$2.7 million in Q1 2026 per GRUSF's latest filing, from -$5335.5 billion in the prior quarter.
- Across five years, Profit After Tax topped out at $12406.7 billion in Q4 2024 and bottomed at -$5335.5 billion in Q4 2025.
- The 5-year median for Profit After Tax is $411979.0 (2023), against an average of $615.9 billion.
- Across the five-year window, Profit After Tax jumped 1845069479.4% in 2024 and slumped 463.75% in 2026, its largest moves.
- Year by year, Profit After Tax stood at $155441.0 in 2022, then soared by 332.59% to $672427.0 in 2023, then soared by 1845069479.4% to $12406.7 billion in 2024, then plunged by 143.01% to -$5335.5 billion in 2025, then surged by 100.0% to -$2.7 million in 2026.
- Per Business Quant, the three latest GRUSF Profit After Tax figures stand at -$2.7 million (Q1 2026), -$5335.5 billion (Q4 2025), and $2835.1 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 369.00 Mn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | -2.35 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 274.90 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Grown Rogue International | 99.32 Mn | 85.61 Mn | 3.96 Mn | -2.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.70 Mn |
| Dec 31, 2025 | -5,335.55 Bn |
| Sep 30, 2025 | 2,835.15 Bn |
| Jun 30, 2025 | 1.42 Mn |
| Mar 31, 2025 | 742,870.00 |
| Dec 31, 2024 | 12,406.75 Bn |
| Sep 30, 2024 | -667.24 Bn |
| Jun 30, 2024 | -5.54 Mn |
| Mar 31, 2024 | -4.17 Mn |
| Dec 31, 2023 | 672,427.00 |
| Oct 31, 2023 | -1.25 Mn |
| Jul 31, 2023 | 757,467.00 |
| Apr 30, 2023 | 411,979.00 |
| Jan 31, 2023 | 592,537.00 |
| Jan 31, 2022 | 155,441.00 |
| Oct 31, 2021 | 1.10 Mn |
| Jul 31, 2021 | 240,294.00 |
| Apr 30, 2021 | 1.44 Mn |
| Jan 31, 2021 | 995,789.00 |
| Oct 31, 2020 | -122,401.00 |